FMS Stock Recent News

Novo Nordisk ended a phase 3 trial early for Ozempic for preventing kidney disease because the trial was so successful. Fresenius and other dialysis-connected companies saw their shares fall on Wednesday.

The trial success of Novo Nordisk's hit drug against kidney failure sent shares of a German kidney dialysis services firm plummeting on Wednesday.

Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.

Fresenius Medical (FMS) gets FDA clearance for Versi HD with GuideMe Software, a portable, home hemodialysis device with an easy-to-use graphical interface providing easier training experiences.

Fresenius Medical's (FMS) second-quarter revenues benefit from strong performance across all segments. Inflationary pressure continues to improve, benefiting operating income.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS ) Q2 2023 Earnings Conference Call August 2, 2023 9:30 AM ET Company Participants Dominik Heger - Head of Investor Relations Helen Giza - Chief Executive Officer and acting Chief Financial Officer Conference Call Participants Victoria Lambert - Berenberg Veronika Dubajova - Citi Richard Felton - Goldman Sachs Hassan Al-Wakeel - Barclays Oliver Metzger - ODDO BHF James Vane-Tempest - Jefferies International Limited Lisa Clive - A.D. Bernstein David Adlington - JPMorgan Christoph Gretler - Credit Suisse Falko Friedrichs - Deutsche Bank Hugo Solvet - BNP Paribas Exane Operator Ladies and gentlemen, thank you for standing by.

Fresenius Medical Care is the world's leading full-service provider of dialysis care and benefits from the entire value chain thanks to its vertical integration. Despite its market-leading position, Fresenius has been a poor performer, with disappointing returns on invested capital and high turnover rates pointing to internal problems. The article takes a look at Fresenius' operational challenges and provides an update on the company's balance sheet against the backdrop of the current interest rate environment.

The move is meant to allow better and timelier decision-making. Fresenius operates dialysis facilities across the world.

Fresenius Medical Care said on Friday that shareholders voted with a 99.88% majority in favour of a change that will simplify its governance and make parent Fresenius SE a regular minority shareholder.

Shares in kidney dialysis group Fresenius Medical Care declined 1.7% at market open in Germany on Tuesday after a payment increase proposed by a major U.S. public health insurance body fell short of market expectations.